Naluzotan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Naluzotan
Accession Number
DB05562
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
PRX-00023
Categories
UNII
LQ54E5B4EW
CAS number
740873-06-7
Weight
Average: 450.64
Monoisotopic: 450.266462274
Chemical Formula
C23H38N4O3S
InChI Key
SPWZXWDPAWDKQE-UHFFFAOYSA-N
InChI
InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
IUPAC Name
N-(3-{4-[4-(cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide
SMILES
CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1

Pharmacology

Indication

Investigated for use/treatment in anxiety disorders and depression.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Naluzotan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AmphetamineThe metabolism of Naluzotan can be decreased when combined with Amphetamine.Approved, Illicit, Investigational
BenmoxinThe metabolism of Naluzotan can be decreased when combined with Benmoxin.Withdrawn
BrofaromineThe metabolism of Naluzotan can be decreased when combined with Brofaromine.Experimental
BromocriptineBromocriptine may increase the vasoconstricting activities of Naluzotan.Approved, Investigational
CabergolineCabergoline may increase the vasoconstricting activities of Naluzotan.Approved
CaroxazoneThe metabolism of Naluzotan can be decreased when combined with Caroxazone.Withdrawn
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Naluzotan.Approved, Investigational
DroxidopaNaluzotan may increase the hypertensive activities of Droxidopa.Approved, Investigational
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Naluzotan.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Naluzotan.Approved
ErgotamineErgotamine may increase the vasoconstricting activities of Naluzotan.Approved
FurazolidoneThe metabolism of Naluzotan can be decreased when combined with Furazolidone.Approved, Investigational, Vet Approved
HarmalineThe metabolism of Naluzotan can be decreased when combined with Harmaline.Experimental
HydracarbazineThe metabolism of Naluzotan can be decreased when combined with Hydracarbazine.Experimental
IproclozideThe metabolism of Naluzotan can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Naluzotan can be decreased when combined with Iproniazid.Withdrawn
IsocarboxazidThe metabolism of Naluzotan can be decreased when combined with Isocarboxazid.Approved
MebanazineThe metabolism of Naluzotan can be decreased when combined with Mebanazine.Withdrawn
Methylene blueThe metabolism of Naluzotan can be decreased when combined with Methylene blue.Approved, Investigational
MethylergometrineMethylergometrine may increase the vasoconstricting activities of Naluzotan.Approved
MinaprineThe metabolism of Naluzotan can be decreased when combined with Minaprine.Approved
MoclobemideThe metabolism of Naluzotan can be decreased when combined with Moclobemide.Approved, Investigational
NialamideThe metabolism of Naluzotan can be decreased when combined with Nialamide.Withdrawn
OctamoxinThe metabolism of Naluzotan can be decreased when combined with Octamoxin.Withdrawn
PargylineThe metabolism of Naluzotan can be decreased when combined with Pargyline.Approved
PhenelzineThe metabolism of Naluzotan can be decreased when combined with Phenelzine.Approved
PheniprazineThe metabolism of Naluzotan can be decreased when combined with Pheniprazine.Withdrawn
PhenoxypropazineThe metabolism of Naluzotan can be decreased when combined with Phenoxypropazine.Withdrawn
PirlindoleThe metabolism of Naluzotan can be decreased when combined with Pirlindole.Approved
PivhydrazineThe metabolism of Naluzotan can be decreased when combined with Pivhydrazine.Withdrawn
ProcarbazineThe metabolism of Naluzotan can be decreased when combined with Procarbazine.Approved, Investigational
RasagilineThe metabolism of Naluzotan can be decreased when combined with Rasagiline.Approved
SafrazineThe metabolism of Naluzotan can be decreased when combined with Safrazine.Withdrawn
SelegilineThe metabolism of Naluzotan can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
ToloxatoneThe metabolism of Naluzotan can be decreased when combined with Toloxatone.Approved
Trans-2-PhenylcyclopropylamineThe metabolism of Naluzotan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Naluzotan can be decreased when combined with Tranylcypromine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
9605731
BindingDB
50187377
ChEMBL
CHEMBL209821

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2TerminatedTreatmentEpilepsies / Epilepsy, Localization Related / Temporal Lobe Epilepsy1
3CompletedTreatmentAnxiety Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0489 mg/mLALOGPS
logP2.68ALOGPS
logP2.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)11.08ChemAxon
pKa (Strongest Basic)7.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area81.75 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity127.77 m3·mol-1ChemAxon
Polarizability51.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:26 / Updated on January 05, 2018 16:02